中宠股份(002891) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥878,035,956.35, representing a 24.42% increase compared to ¥705,704,475.31 in the same period last year[7] - Net profit attributable to shareholders was ¥56,224,262.21, a significant increase of 259.00% from ¥15,661,481.13 in the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥53,900,771.60, up 298.05% from ¥13,541,284.12 year-on-year[7] - Basic earnings per share increased to ¥0.1914, reflecting a growth of 259.77% from ¥0.0532 in the same quarter last year[7] - Net profit for the current period was ¥65,054,355.02, representing a significant increase of 141.1% from ¥27,014,542.48 in the previous period[23] - The company's operating profit rose to ¥81,778,100.10, compared to ¥34,159,436.86 in the last period, marking an increase of 139.7%[23] - Total operating revenue for the current period reached ¥878,035,956.35, an increase of 24.4% compared to ¥705,704,475.31 in the previous period[22] - Basic and diluted earnings per share increased to ¥0.1914, compared to ¥0.0532 in the previous period, reflecting a growth of 259.4%[24] - The total comprehensive income attributable to the parent company was ¥26,181,975.28, up from ¥5,061,429.28 in the previous period[24] Cash Flow and Liquidity - The company's cash flow from operating activities improved to -¥13,214,250.87, a 50.11% reduction in losses compared to -¥26,489,023.30 in the previous year[7] - The net cash flow from operating activities was -¥13,214,250.87, improving from -¥26,489,023.30 in the previous period[25] - The net cash flow from investing activities was ¥261,422,552.00, a significant recovery from -¥87,726,761.51 in the previous period[26] - The net cash flow from financing activities was -¥258,819,018.82, worsening from -¥72,419,653.11 in the previous period[26] - The cash and cash equivalents at the end of the period were ¥413,818,117.99, a decrease from ¥419,866,000.98 at the beginning of the period[26] - The company's cash and cash equivalents at the end of the reporting period amount to ¥495,954,492.34, down from ¥527,140,490.48 at the beginning of the period, representing a decrease of approximately 5.5%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,062,552,911.27, down 7.46% from ¥4,390,215,978.74 at the end of the previous year[7] - Total liabilities decreased to ¥1,648,652,566.30 from ¥1,970,843,441.21, a reduction of 16.4%[20] - The total current assets decreased from ¥2,021,544,407.72 to ¥1,732,955,258.61, a decline of about 14.3%[18] - The company's equity attributable to shareholders increased slightly to ¥2,234,016,056.29 from ¥2,232,803,268.30, a marginal increase of 0.1%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 24,744[17] - The largest shareholder, Yantai Zhongxing Biotechnology Co., Ltd., holds 24.86% of the shares, totaling 73,125,750 shares[17] Expenses and Costs - Total operating costs amounted to ¥793,502,618.62, up 19.2% from ¥665,481,404.42 in the prior period[22] - Sales expenses rose by 33.55% to ¥9,113.25, primarily due to increased promotional costs associated with business growth[14] - Research and development expenses increased to ¥14,789,530.45, up from ¥12,637,426.51, reflecting a growth of 17.0%[22] - Cash paid for taxes increased by 47.67% to ¥2,116.17, reflecting higher income and profit levels[16] Other Financial Activities - The company received government subsidies amounting to ¥1,374,916.18, contributing to a 49.86% increase in other income[8] - The company reported an investment income of ¥6,075,506.48, a recovery from a loss of ¥4,152,220.68 in the previous period[23] - The company received cash inflows from investment activities totaling ¥470,286,039.88, compared to ¥359,795,601.16 in the previous period[26] - The cash outflow for purchasing goods and services was ¥642,830,801.84, an increase from ¥558,299,566.32 in the previous period[25] Inventory and Receivables - Accounts receivable increased to ¥504,592,406.01 from ¥467,593,674.70, reflecting an increase of about 7.5%[18] - Inventory at the end of the reporting period is ¥632,798,553.84, up from ¥580,461,671.50, indicating an increase of approximately 9%[18] Other Notes - The company has not reported any changes in the shareholding structure of major shareholders due to securities lending activities[18] - There are no preferred shareholders or significant changes in the number of preferred shareholders reported[18] - The company has not disclosed any new strategies or developments in product or technology during this reporting period[18] - No mergers or market expansion activities have been mentioned in the current report[18] - The company reported a foreign currency translation loss of ¥30,042,286.93, compared to a loss of ¥12,002,751.85 in the previous period[24]